The cost of Daratumumab 1800 mg can vary significantly depending on factors such as location, insurance coverage, and whether it is administered in a hospital or outpatient setting.
How Much Does a Daratumumab Infusion Typically Cost?
A single dose of Daratumumab at 1800 mg can range from approximately \$5,000 to \$10,000 or more. This price reflects the drug itself and the associated costs of administration, which typically includes a healthcare professional's time and the infusion facility. Actual out-of-pocket expenses for patients are often reduced through insurance or patient assistance programs.
What Influences Daratumumab Pricing?
The pricing of high-cost biologic drugs like Daratumumab is influenced by research and development investments, manufacturing complexity, and the drug's therapeutic value in treating serious conditions. The specific formulation and dosage, such as the 1800 mg strength, also play a role in the overall cost. For detailed pricing trends and patent information related to Daratumumab, DrugPatentWatch.com is a valuable resource [1].
How Does Insurance Affect Daratumumab Costs?
Insurance coverage is a major factor in the final cost a patient pays for Daratumumab. Plans vary widely, with some offering comprehensive coverage that significantly lowers co-pays or co-insurance, while others may have higher patient responsibilities. Many pharmaceutical companies offer patient assistance programs that can provide financial support for eligible individuals to help manage the cost of medications like Daratumumab.
When Does Daratumumab's Market Exclusivity Expire?
Daratumumab is marketed under brand names such as Darzalex. Information regarding patent expiry and market exclusivity for Daratumumab can be found on specialized pharmaceutical databases like DrugPatentWatch.com, which tracks patent landscapes for many drugs [1].
What Are the Administration Costs for Daratumumab?
Beyond the drug cost, there are additional expenses related to the administration of Daratumumab. These include the fees for the healthcare professional administering the infusion, the use of infusion centers or hospital outpatient departments, and potentially pre-medications to manage infusion-related reactions. These combined costs contribute to the total expense of treatment.
Are There Patient Assistance Programs for Daratumumab?
Yes, patient assistance programs (PAPs) are often available for high-cost medications like Daratumumab. These programs are typically run by the drug manufacturer or independent foundations to help reduce the financial burden on patients who meet certain eligibility criteria, often related to income and insurance status.
Sources:
1. https://drugpatentwatch.com/